MarketCap
Facebook
X
TelegramAnnual report 2022
added 12-21-2024
ADC Therapeutics SA Cash and Cash Equivalents 2011-2026 | ADCT
Annual Cash and Cash Equivalents ADC Therapeutics SA
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 326 M | 467 M | 439 M | 116 M | 139 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 467 M | 116 M | 297 M |
Quarterly Cash and Cash Equivalents ADC Therapeutics SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 431 M | 467 M | 530 M | 372 M | 383 M | 439 M | 494 M | 349 M | 82.6 M | 116 M | - | - | - | 139 M | - | - | - | 263 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 530 M | 82.6 M | 339 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioNTech SE
BNTX
|
7.68 B | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | Germany |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
2.6 M | $ 3.54 | -20.81 % | $ 238 B | Britain |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 330.34 | 3.6 % | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
3.22 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
15.3 M | $ 0.79 | 1.22 % | $ 27.9 M |  Israel |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
argenx SE
ARGX
|
3.49 B | $ 748.25 | 0.25 % | $ 25 B |  Niderland |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.89 | -4.33 % | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
AbbVie
ABBV
|
5.23 B | $ 206.69 | -1.01 % | $ 366 B | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.39 | -3.69 % | $ 1.01 B | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Ardelyx
ARDX
|
68 M | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
Genmab A/S
GMAB
|
3.55 B | $ 27.75 | 0.91 % | $ 17.6 B |  Danmark |
|
Cerevel Therapeutics Holdings
CERE
|
416 M | - | - | $ 7.29 B | USA |
 |
Grifols, S.A.
GRFS
|
980 M | $ 8.23 | -0.12 % | $ 6.83 B |  Spain |
 |
Akebia Therapeutics
AKBA
|
185 M | $ 1.32 | -4.35 % | $ 339 M | USA |